MATTAWAN, April 5, 2007: MPI Research is pleased to be an integral part of the 16th NYBA annual meeting, being held on April 10, 2007 at the Marriott Marquis Hotel in New York City. Stephen Frantz, PhD, DABT, MPI Research Director of Pharmaceutical Development and Senior Principal Study Director, will be one of three panelists discussing “FDA Requirements for New Drug Development – Enabling Your IND.” NYBA will sponsor fifteen panel discussions on crucial and timely topics impacting the biotech industry of both today and tomorrow.

“MPI Research is proud to participate in this important meeting,” says James Laveglia, PhD, Vice President of Research and Development at MPI Research. “A didactic approach such as this is one of many ways we help the biotechnology industry on their journey towards new product development. It is an honor to support NYBA’s mission of advancing the success of the biotech industry.”

The goal of NYBA (www.nyba.org) is to advance the success of the biotech industry in the state of New York. The organization also advocates on behalf of this industry among policymakers. With over 250 New York biotech companies as member organizations, NYBA will continue to provide opportunities for learning and collegiality under its manner of ”The Cure Stops Here®.”

MPI Research, with headquarters in Mattawan, Michigan, is one of the worlds leading providers of comprehensive preclinical research and development services. More information on the company’s services can be obtained through the website at www.mpiresearch.com.


Home | News